株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

ヒトマイクロバイオームの世界市場:考察、機会、分析、市場シェア、将来予測

Global Human Microbiome Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 - 2023

発行 Occams Business Research & Consulting Pvt. Ltd. 商品コード 496601
出版日 ページ情報 英文 140 Pages
納期: お問合せ
価格
本日の銀行送金レート: 1USD=109.55円で換算しております。
Back to Top
ヒトマイクロバイオームの世界市場:考察、機会、分析、市場シェア、将来予測 Global Human Microbiome Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 - 2023
出版日: 2017年04月03日 ページ情報: 英文 140 Pages
概要

当レポートでは、世界のヒトマイクロバイオームの市場について分析し、技術・市場の概略や最新動向、主な市場促進・阻害要因、市場の機会・課題、製品別・用途別・疾患別および地域別の市場動向予測 (過去3年間・今後7年間分)、競合情勢、市場発展の方向性、主要企業のプロファイルなどを調査しております。

第1章 イントロダクション

第2章 市場概要

  • 世界のヒトマイクロバイオーム市場:発展と遷移
  • 市場の定義と範囲
  • 産業構造
  • 規制枠組み
  • 市場全体の分析
  • 市場推計分析
  • 戦略分析
    • 投資/導入モデル
    • 全方位的な産業分析
    • ポーターのファイブフォース分析
    • シーソー分析
    • 消費者分析と主な購入基準
  • 市場競争分析
    • 主要戦略の分析
    • 市場シェア分析
    • 主要企業の分析
  • 戦略的提言と主な結論
    • 各地域での市場機会
    • 新規分野での市場機会
    • 急成長市場での投資機会

第3章 市場の決定要因

  • 市場促進要因
    • ヒトマイクロバイオーム療法の普及
    • 早期の疾患検出・診断への関心
    • 創薬技術の進歩
    • 妥当性の高いモデルの利用
  • 市場抑制要因
    • 専門的な技術/市場知識の欠如
    • 包括的アプローチの欠如
    • 早期検出・診断の障害
    • 使用上の利点に関する認識の低さ
  • 市場機会
    • 研究開発 (R&D) 投資額の拡大
    • 新薬への投資
    • 新興国市場の成長
    • 世界規模での巨大な市場機会
  • 市場の課題
    • 新技術の市場参入障壁
    • 政府の厳格な規制

第4章 市場区分

  • 世界のヒトマイクロバイオーム市場:製品別
    • 市場の定義と範囲
    • 意思決定支援データベースおよび推計手法
    • 市場間の比較分析
    • 市場機会マトリックス
    • 市場区分
      • プロバイオティクス
      • 食品
      • プレバイオティクス
      • 医療食
      • 診断サービス
      • 薬剤
      • その他
  • 世界のヒトマイクロバイオーム市場:用途別
    • 治療用
    • 診断用
  • 世界のヒトマイクロバイオーム市場:疾患別
    • 急性下痢
    • 肥満症
    • 糖尿病
    • 自己免疫障害
    • がん
    • 精神障害

第5章 競争環境

  • 主な戦略
    • 企業合併・買収 (M&A) の一覧
    • 合弁事業 (JV) の一覧
    • 製品発売の一覧
    • 事業提携の一覧
  • 上位企業10社の分析

第6章 世界のヒトマイクロバイオーム市場:地域別

  • 意思決定支援データベースおよび推計手法
  • 市場間の比較分析
  • 市場機会マトリックス
  • 地域別の市場分析
    • 北米市場
    • 欧州市場 (英国、ドイツ、スペイン、イタリア、フランスなど)
    • アジア太平洋地域市場 (中国、インド、日本、韓国、オーストラリアなど)
    • 他の国々 (RoW) (ラテンアメリカ、中東・アフリカ)

第7章 企業プロファイル

目次
Product Code: HBI-4740317

The global human Microbiome market is expected to grow at a CAGR of 20.4%. The main driver of the global human Microbiome market is frequent use of probiotics, medical foods and prebiotics. Probiotics are those products which contains live bacteria and yeasts that are good for health, especially for digestive system. Generally bacteria are those living organisms that cause diseases. Body consists of bacteria, both good and bad. Probiotics are generally called "good" or "helpful" bacteria because they help to keep body healthy. Probiotics are naturally found in the body. Some foods and supplements contains probiotic bacteria which on consumption gives benefits to the body such as Bifidobacterium is beneficial in treatment of infant diarrhea Continuous consumption of antibiotics can increase demand of efficient and safe medication but sometime it give rise to reaction also if it doesn't suits the person.

The global human Microbiome market is segmented into by product, by application, and by disease. By Product can be further divided into probiotics, food supplements, prebiotics, drugs, medical devices, diagnostic devices, other probiotic supplements. Application type segment can be further classified into therapeutics, diagnostics. By disease segment can be further classified into acute diarrhea, obesity, diabetics, cancer, mental disorder, autoimmune disorder.

On the basis of Geography global human Microbiome market is divided into four major regions North America, Europe, and Asia-pacific, rest of the world. North American region is the emerging market because of government initiatives and support in the study of life sciences. Europe region are the major contributor in human Microbiome market with immense potential and opportunities and innovations in drug based on bacterial consortia. Additionally, changes in lifestyle led to increase in number of diseases, rise in population is another factor contributing in the increase of the diseases and is one of the major driver for the global microbiome market. Cancer and diabetics are some major disease increasing day by day In the Asia pacific region there are approximately 300000 new cases of cancer and diabetics, which is more than half of the total cases globally. China and India are key emerging nation across the globe. China has biggest influence on Asia Pacific region growth. It is estimated that there were 4.3 million new cancer cases found, which around 2.8 million in 2015 were.

Some of the major players of the human Microbiome market are Vedanta Biosciences, ritter pharmaceuticals, Actoginics, avidbiotics, rebiotix, osel, , Miomics, E.I. du Pont de Nemours, Second Genome. Ritter Pharmaceuticals Company of USA develops new range of therapeutic products that balance the stomach Microorganisms to cure diseases related to stomach and intestine. Its key product is RP-G28 that have the ability that lead to future usefulness. and become the first USFDA approved therapy for lactose intolerance, also for metabolic and liver disease One of the key strategies of Ritter Pharmaceuticals, Inc. has associated with Food and Health Center at University of Nebraska in US to examine the role of human microorganisms.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

  • 2.1. GLOBAL HUMAN MICROBIOME MARKET: EVOLUTION AND TRANSITION
  • 2.2. MARKET DEFINATION AND SCOPE
  • 2.3. INDUSTRY STRUCTURE
  • 2.4. REGULATORY FRAMEWORK
  • 2.5. TOTAL MARKET ANALYSIS
    • 2.5.1. TOP 5 FINDINGS
    • 2.5.2. TOP 5 OPPORTUNITY MARKETS
    • 2.5.3. TOP 5 COMPANIES
    • 2.5.4. TOP 3 COMPETITIVE STRATEGIES
  • 2.6. ESTIMATION ANALYSIS
  • 2.7. STRATEGIC ANALYSIS
    • 2.7.1. INVESTMENT VS. ADOPTION MODEL
    • 2.7.2. 360 DEGREE INDUSTRY ANALYSIS
    • 2.7.3. PORTERS 5 FORCE MODEL
    • 2.7.4. SEE-SAW ANALYSIS
    • 2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
  • 2.8. COMPETITIVE ANALYSIS
    • 2.8.1. MARKET SHARE ANALYSIS
    • 2.8.2. MARKET ANALYSIS
    • 2.8.3. TOP COMPANY ANALYSIS
  • 2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
    • 2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
    • 2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
    • 2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT

3. MARKET DETERMINANTS

  • 3.1. MARKET DRIVERS
    • 3.1.1. INCREASED ADOPTION OF HUMAN MICROBIOME THERAPY
    • 3.1.2. FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS
    • 3.1.3. GROWING TECHNOLOGICAL DRUG DEVELOPMENT
    • 3.1.4. USE OF HIGH VALIDATION MODEL
  • 3.2. MARKET RESTRAINTS
    • 3.1.5. LACK OF TECHNOLOGICAL MARKET EXPERTISE
    • 3.1.6. LACK OF COMPREHENSIVE APPORACH
    • 3.1.7. BARRIERS IN EARLY DETECTION AND DIAGNOSIS
    • 3.1.8. MINIMAL AWARENESS REGARDING THE BENEFICIAL USE
  • 3.2. MARKET OPPORTUNITIES
    • 3.2.1. GROWING R&D INVESTMENT
    • 3.2.2. INVESTMENT ON NEW DRUGS
    • 3.2.3. INCREASING GROWTH IN EMERGING MARKET
    • 3.2.4. HIGH GLOBAL OPPORTUNITIES
  • 3.3. MARKET CHALLENGES
    • 3.3.1. BARRIER FOR NEW TECHNOLOGY TO ENTER INTO MARKET
    • 3.3.2. STRINGENT GOVERNMENT REGULATIONS

4. MARKET SEGMENTATION

  • 4.1. GLOBAL HUMAN MICROBIOME MARKET BY PRODUCT
    • 4.1.1. MARKET DEFINITION AND SCOPE
    • 4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.1.4. OPPORTUNITY MATRIX
    • 4.1.5. MARKET SEGMENTATION
      • 4.1.5.1. BY PROBIOTICS
        • 4.1.5.1.1. APPLICATIONS
        • 4.1.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.1.5.1.4. TOP PLAYERS & KEY PRODUCTS
        • 4.1.5.1.5. KEY CONCLUSIONS
      • 4.1.5.2. BY FOODS
        • 4.1.5.2.1. APPLICATIONS
        • 4.1.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.1.5.2.4. TOP PLAYERS & KEY PRODUCTS
        • 4.1.5.2.5. KEY CONCLUSIONS
      • 4.1.5.3. BY PREBIOTICS
        • 4.1.5.3.1. APPLICATIONS
        • 4.1.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.5.3.4. TOP PLAYERS & KEY PRODUCTS
        • 4.1.5.3.5. KEY CONCLUSIONS
      • 4.1.5.4. BY MEDICAL FOODS
        • 4.1.5.4.1. APPLICATIONS
        • 4.1.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.5.4.4. TOP PLAYERS & KEY PRODUCTS
        • 4.1.5.4.5. KEY CONCLUSIONS
      • 4.1.5.5. BY DIAGNOSTIC DEVICES
        • 4.1.5.5.1. APPLICATIONS
        • 4.1.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.5.5.4. TOP PLAYERS & KEY PRODUCTS
        • 4.1.5.5.5. KEY CONCLUSIONS
      • 4.1.5.6. BY DRUGS
        • 4.1.5.6.1. APPLICATIONS
        • 4.1.5.6.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.6.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.5.6.4. TOP PLAYERS & KEY PRODUCTS
        • 4.1.5.6.5. KEY CONCLUSIONS
      • 4.1.5.7. BY OTHER PROBIOTIC SUPPLEMENTS
        • 4.1.5.7.1. APPLICATIONS
        • 4.1.5.7.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.7.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.5.7.4. TOP PLAYERS & KEY PRODUCTS
        • 4.1.5.7.5. KEY CONCLUSIONS
  • 4.2. GLOBAL HUMAN MICROBIOME MARKET BY APPLICATION
    • 4.2.1. MARKET DEFINITION AND SCOPE
    • 4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.2.4. OPPORTUNITY MATRIX
    • 4.2.5. MARKET SEGMENTATION 2014-2023($ MILLION)
      • 4.2.5.1. THERAPEUTICS
        • 4.2.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.2.5.1.3. TOP PLAYERS & KEY PRODUCTS
        • 4.2.5.1.4. KEY CONCLUSIONS
      • 4.2.5.2. DIAGNOSTICS
        • 4.2.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.2.5.2.3. TOP PLAYERS & KEY PRODUCTS
        • 4.2.5.2.4. KEY CONCLUSIONS
  • 4.3. GLOBAL HUMAN MICROBIOME MARKET BY DISEASE
    • 4.3.1. MARKET DEFINITION AND SCOPE
    • 4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.3.4. OPPORTUNITY MATRIX
    • 4.3.5. MARKET SEGMENTATION
      • 4.3.5.1. ACUTE DIARRHEA
        • 4.3.5.1.1. APPLICATIONS
        • 4.3.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.3.5.1.4. TOP PLAYERS & KEY PRODUCTS
        • 4.3.5.1.5. KEY CONCLUSIONS
      • 4.3.5.2. OBESITY
        • 4.3.5.2.1. APPLICATIONS
        • 4.3.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.3.5.2.4. TOP PLAYERS & KEY PRODUCTS
        • 4.3.5.2.5. KEY CONCLUSIONS
      • 4.3.5.3. DIABETES
        • 4.3.5.3.1. APPLICATIONS
        • 4.3.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.3.5.3.4. TOP PLAYERS & KEY PRODUCTS
        • 4.3.5.3.5. KEY CONCLUSIONS
      • 4.3.5.4. AUTOIMMUNE DISORDER
        • 4.3.5.4.1. APPLICATIONS
        • 4.3.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.3.5.4.4. TOP PLAYERS & KEY PRODUCTS
        • 4.3.5.4.5. KEY CONCLUSIONS
      • 4.3.5.5. CANCER
        • 4.3.5.5.1. APPLICATIONS
        • 4.3.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.3.5.5.4. TOP PLAYERS & KEY PRODUCTS
        • 4.3.5.5.5. KEY CONCLUSIONS
      • 4.3.5.6. MENTAL DISORDER
        • 4.3.5.6.1. APPLICATIONS
        • 4.3.5.6.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.6.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.3.5.6.4. TOP PLAYERS & KEY PRODUCTS
        • 4.3.5.6.5. KEY CONCLUSIONS

5. COMPETITIVE LANDSCAPE

  • 5.1. KEY STRATEGIES
    • 5.1.1. LIST OF M&A
    • 5.1.2. LIST OF JV
    • 5.1.3. LIST OF PRODUCT LAUNCHES
    • 5.1.4. LIST OF PARTNERSHIP
  • 5.2. TOP 10 COMPANY ANALYSIS

6. GLOBAL HUMAN MICROBIOME MARKET BY REGION 2014-2023 ($MILLION)

  • 6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 6.3. OPPORTUNITY MATRIX
  • 6.4. GEOGRAPHIC SEGMENTATION
    • 6.4.1. NORTH AMERICA
      • 6.4.1.1. INDUSTRIAL APPLICATION ANALYSIS
      • 6.4.1.2. TOP COUNTRY ANALYSIS
        • 6.4.1.2.1. U.S.
          • 6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.1.2.1.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.1.2.1.3. KEY CONCLUSIONS
        • 6.4.1.2.2. CANADA
          • 6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.1.2.2.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.1.2.2.3. KEY CONCLUSIONS
    • 6.4.2. EUROPE
      • 6.4.2.1. INDUSTRY APPLICATION ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.2.2. TOP COUNTRY ANALYSIS
        • 6.4.2.2.1. UK
          • 6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.1.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.1.3. KEY CONCLUSIONS
        • 6.4.2.2.2. GERMANY
          • 6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.2.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.2.3. KEY CONCLUSIONS
        • 6.4.2.2.3. SPAIN
          • 6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.3.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.3.3. KEY CONCLUSIONS
        • 6.4.2.2.4. ITALY
          • 6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.4.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.4.3. KEY CONCLUSIONS
        • 6.4.2.2.5. FRANCE
          • 6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.5.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.5.3. KEY CONCLUSIONS
        • 6.4.2.2.6. REST OF EUROPE
          • 6.4.2.2.6.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.6.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.6.3. KEY CONCLUSIONS
    • 6.4.3. ASIA PACIFIC
      • 6.4.3.1. INDUSTRY APPLICATION ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.3.2. TOP COUNTRY ANALYSIS
        • 6.4.3.2.1. CHINA
          • 6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.1.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.1.3. KEY CONCLUSIONS
        • 6.4.3.2.2. INDIA
          • 6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.2.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.2.3. KEY CONCLUSIONS
        • 6.4.3.2.3. JAPAN
          • 6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.3.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.3.3. KEY CONCLUSIONS
        • 6.4.3.2.4. SOUTH KOREA
          • 6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.4.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.4.3. KEY CONCLUSIONS
        • 6.4.3.2.5. AUSTRALIA
          • 6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.5.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.5.3. KEY CONCLUSIONS
        • 6.4.3.2.6. REST OF ASIA PACIFIC
          • 6.4.3.2.6.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.6.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.6.3. KEY CONCLUSIONS
    • 6.4.4. ROW
      • 6.4.4.1. INDUSTRY APPLICATION ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.4.2. TOP COUNTRY ANALYSIS
        • 6.4.4.2.1. LATIN AMERICA
          • 6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.4.2.1.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.4.2.1.3. KEY CONCLUSIONS
        • 6.4.4.2.2. MIDDLE EAST & AFRICA
          • 6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
          • 6.4.4.2.2.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.4.2.2.3. KEY CONCLUSIONS

7. COMPANY PROFILES

    • 7.1.1. ACTOGENIX
      • 7.1.1.1. OVERVIEW
      • 7.1.1.2. PRODUCT PORTFOLIO
      • 7.1.1.3. KEY INOVATION SECTOR
      • 7.1.1.4. STRATEGIC INITIATIVES
      • 7.1.1.5. SCOT ANALYSIS
      • 7.1.1.6. STRATEGIC ANALYSIS
  • 7.2. AVIDBIOTICS
    • 7.2.1. OVERVIEW
    • 7.2.2. PRODUCT PORTFOLIO
    • 7.2.3. KEY INOVATION SECTOR
    • 7.2.4. STRATEGIC INITIATIVES
    • 7.2.5. SCOT ANALYSIS
    • 7.2.6.
  • 7.3. ENTEROLOGICS
    • 7.3.1. OVERVIEW
    • 7.3.2. PRODUCT PORTFOLIO
    • 7.3.3. KEY INOVATION SECTOR
    • 7.3.4. STRATEGIC INITIATIVES
    • 7.3.5. SCOT ANALYSIS
    • 7.3.6. STRATEGIC ANALYSIS
  • 7.4. ENTEROME BIOSCIENCE
    • 7.4.1. OVERVIEW
    • 7.4.2. PRODUCT PORTFOLIO
    • 7.4.3. KEY INOVATION SECTOR
    • 7.4.4. STRATEGIC INITIATIVES
    • 7.4.5. SCOT ANALYSIS
    • 7.4.6. STRATEGIC ANALYSIS
  • 7.5. METABIOMICS
    • 7.5.1. OVERVIEW
    • 7.5.2. PRODUCT PORTFOLIO
    • 7.5.3. KEY INOVATION SECTOR
    • 7.5.4. STRATEGIC INITIATIVES
    • 7.5.5. SCOT ANALYSIS
    • 7.5.6. STRATEGIC ANALYSIS
  • 7.6. MICROBIOME THERAPEUTICS LLC
    • 7.6.1. OVERVIEW
    • 7.6.2. PRODUCT PORTFOLIO
    • 7.6.3. KEY INOVATION SECTOR
    • 7.6.4. STRATEGIC INITIATIVES
    • 7.6.5. SCOT ANALYSIS
    • 7.6.6. STRATEGIC ANALYSIS
  • 7.7. METABOGEN
    • 7.7.1. OVERVIEW
    • 7.7.2. PRODUCT PORTFOLIO
    • 7.7.3. KEY INOVATION SECTOR
    • 7.7.4. STRATEGIC INITIATIVES
    • 7.7.5. SCOT ANALYSIS
    • 7.7.6. STRATEGIC ANALYSIS
  • 7.8. MIOMICS
    • 7.8.1. OVERVIEW
    • 7.8.2. PRODUCT PORTFOLIO
    • 7.8.3. KEY INOVATION SECTOR
    • 7.8.4. STRATEGIC INITIATIVES
    • 7.8.5. SCOT ANALYSIS
    • 7.8.6. STRATEGIC ANALYSIS
  • 7.9. OSEL
    • 7.9.1. OVERVIEW
    • 7.9.2. PRODUCT PORTFOLIO
    • 7.9.3. KEY INOVATION SECTOR
    • 7.9.4. STRATEGIC INITIATIVES
    • 7.9.5. SCOT ANALYSIS
    • 7.9.6. STRATEGIC ANALYSIS
  • 7.10. REBIOTIX
    • 7.10.1. OVERVIEW
    • 7.10.2. PRODUCT PORTFOLIO
    • 7.10.3. KEY INOVATION SECTOR
    • 7.10.4. STRATEGIC INITIATIVES
    • 7.10.5. SCOT ANALYSIS
    • 7.10.6. STRATEGIC ANALYSIS
  • 7.11. RITTER PHARMACEUTICALS
    • 7.11.1. OVERVIEW
    • 7.11.2. PRODUCT PORTFOLIO
    • 7.11.3. KEY INOVATION SECTOR
    • 7.11.4. STRATEGIC INITIATIVES
    • 7.11.5. SCOT ANALYSIS
    • 7.11.6. STRATEGIC ANALYSIS
  • 7.12. SECOND GENOME
    • 7.12.1. OVERVIEW
    • 7.12.2. PRODUCT PORTFOLIO
    • 7.12.3. KEY INOVATION SECTOR
    • 7.12.4. STRATEGIC INITIATIVES
    • 7.12.5. SCOT ANALYSIS
    • 7.12.6. STRATEGIC ANALYSIS
  • 7.13. SYMBERIX
    • 7.13.1. OVERVIEW
    • 7.13.2. PRODUCT PORTFOLIO
    • 7.13.3. KEY INOVATION SECTOR
    • 7.13.4. STRATEGIC INITIATIVES
    • 7.13.5. SCOT ANALYSIS
    • 7.13.6. STRATEGIC ANALYSIS
  • 7.14. SYMBIOTIX BIOTHERAPICS
    • 7.14.1. OVERVIEW
    • 7.14.2. PRODUCT PORTFOLIO
    • 7.14.3. KEY INOVATION SECTOR
    • 7.14.4. STRATEGIC INITIATIVES
    • 7.14.5. SCOT ANALYSIS
    • 7.14.6. STRATEGIC ANALYSIS
  • 7.15. VEDANTA
    • 7.15.1. OVERVIEW
    • 7.15.2. PRODUCT PORTFOLIO
    • 7.15.3. KEY INOVATION SECTOR
    • 7.15.4. STRATEGIC INITIATIVES
    • 7.15.5. SCOT ANALYSIS
    • 7.15.6. STRATEGIC ANALYSIS

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN MICROBIOME MARKET BY PRODUCT 2014-2023 ($ MILLION)
  • TABLE 2. GLOBAL PROBIOTICS HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($MILLION)
  • TABLE 3. GLOBAL FOODS HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 4. GLOBAL PREBIOTICS HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023($ MILLION)
  • TABLE 5. GLOBAL MEDICAL FOODS HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 6. GLOBAL DRUGS HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 7. GLOBAL DIAGNOSTICS DEVICES HUMAN MICROBIOME MARKET GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 8. GLOBAL BY OTHER PROBIOTICS SUPPLEMENTS HUMAN MICROBIOME MARKET GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 9. GLOBAL HUMAN MICROBIOME MARKET BY APPLICATION 2014-2023 ($ MILLION)
  • TABLE 10. GLOBAL THERAPEUTICS HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 11. GLOBAL DIAGNOSTICS HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 12. GLOBAL HUMAN MICROBIOME MARKET BY DISEASE 2014-2023 ($ MILLION)
  • TABLE 13. GLOBAL ACUTE DIARRHEA HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 14. GLOBAL OBESITY HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 15. GLOBAL DIABETICS HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 16. GLOBAL CANCER HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISORDER HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 18. GLOBAL MENTAL DISORDER HUMAN MICROBIOME MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 19. NORTH AMERICA HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)
  • TABLE 20. EUROPE HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)20
  • TABLE 21. ASIA PACIFIC HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)
  • TABLE 22. REST OF THE WORLD HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN MICROBIOME MARKET BY FOOD 2014-2023 ($ MILLION)
  • FIGURE 2. GLOBAL HUMAN MICROBIOME MARKET PROBIOTICS 2014-2023 ($ MILLION)
  • FIGURE 3. GLOBAL HUMAN MICROBIOME MARKET PREBIOTICS 2014-2023 ($ MILLION)
  • FIGURE 4. GLOBAL HUMAN MICROBIOME MARKET MEDICAL FOODS 2014-2023 ($ MILLION)
  • FIGURE 5. GLOBAL HUMAN MICROBIOME MARKET DIAGNOSTIC DEVICES 2014-2023 ($ MILLION)
  • FIGURE 6. GLOBAL HUMAN MICROBIOME MARKET DRUGS 2014-2023 ($ MILLION)
  • FIGURE 7. GLOBAL HUMAN MICROBIOME MARKET OTHER PROBIOTICS SUPPLEMENT 2014-2023 ($ MILLION)
  • FIGURE 8. GLOBAL HUMAN MICROBIOME MARKET THERAPEUTICS 2014-2023 ($ MILLION)
  • FIGURE 9. GLOBAL HUMAN MICROBIOME MARKET DIAGNOSTICS 2014-2023 ($ MILLION)
  • FIGURE 10. GLOBAL HUMAN MICROBIOME MARKET ACUTE DIARRHEA 2014-2023 ($ MILLION)
  • FIGURE 11. GLOBAL HUMAN MICROBIOME MARKET OBESITY 2014-2023 ($ MILLION)
  • FIGURE 12. GLOBAL HUMAN MICROBIOME MARKET DIABETICS 2014-2023 ($ MILLION)
  • FIGURE 13. GLOBAL HUMAN MICROBIOME MARKET CANCER 2014-2023 ($ MILLION)
  • FIGURE 14. GLOBAL HUMAN MICROBIOME MARKET AUTOIMMUNE DISORDER 2014-2023 ($ MILLION)
  • FIGURE 15. GLOBAL HUMAN MICROBIOME MARKET MENTAL DISORDER 2014-2023 ($ MILLION)
  • FIGURE 16. UNITED STATES (U.S.) HUMAN MICROBIOME MARKET2014-2023 ($ MILLION)
  • FIGURE 17. CANADA HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)
  • FIGURE 18. UNITED KINGDOM (UK) HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)
  • FIGURE 19. GERMANY HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)
  • FIGURE 20. SPAIN HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)
  • FIGURE 21. ITALY HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)
  • FIGURE 22. FRANCE HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)
  • FIGURE 23. ROE HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)
  • FIGURE 24. INDIA HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)
  • FIGURE 25. CHINA HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)
  • FIGURE 26. JAPAN HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)
  • FIGURE 27. KOREA HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)
  • FIGURE 28. ROWAPAC HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)
  • FIGURE 29. LATIN AMERICA HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)
  • FIGURE 30. MENA HUMAN MICROBIOME MARKET 2014-2023 ($ MILLION)
Back to Top